VRTX · XBRL financial data

Vertex Pharmaceuticals financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VRTX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	6,206	7,574	8,931	9,869	11,020	12,001
Cost of goods and services sold	736	904	1,080	1,262	1,531	1,651
Research and development	1,830	3,051	—	—	—	—
Selling, general and administrative	770	840	945	1,137	1,464	1,753
Operating income (loss)	2,856	2,782	4,307	3,832	(233)	4,173
Interest expense	58	—	55	44	31	13
Other income (expense)	296	5	(165)	(23)	(86)	(8)
Income tax expense (benefit)	405	388	910	760	784	690
Net income (loss)	2,712	2,342	3,322	3,620	(536)	3,953
Earnings per share, basic USD per share	10.44	9.09	12.97	14.05	(2.08)	15.46
Earnings per share, diluted USD per share	10.29	9.01	12.82	13.89	(2.08)	15.32
Weighted average shares, basic millions of shares	260	258	256	258	258	256
Weighted average shares, diluted millions of shares	263	260	259	261	258	258

Fiscal years (VRTX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	5,988	6,795	10,504	10,369	4,570	5,085
Marketable securities	671	730	275	849	1,546	1,523
Marketable securities, non-current	—	—	112	2,498	5,108	5,712
Accounts receivable	885	1,137	1,442	1,563	1,609	2,053
Inventory	281	353	461	739	1,205	1,687
Prepaid and other current assets	308	546	554	624	666	853
Total current assets	8,133	9,561	13,235	14,144	9,596	11,201
Right-of-use asset	326	330	347	294	1,357	1,563
Goodwill	1,002	1,002	1,088	1,088	1,088	1,088
Total assets	11,752	13,433	18,151	22,730	22,533	25,643
Accounts payable	155	195	304	365	413	462
Accrued liabilities	1,405	1,679	2,127	2,655	2,789	2,971
Current portion of long-term debt	—	—	—	—	—	0
Total current liabilities	1,878	2,142	2,742	3,547	3,565	3,861
Long-term debt	—	—	—	—	—	0
Lease liability, non-current	350	377	380	349	1,544	1,847
Total liabilities	3,065	3,333	4,238	5,150	6,124	6,977
Retained earnings	859	3,201	6,523	10,142	9,607	13,560
Total stockholders' equity	8,687	10,100	13,913	17,580	16,410	18,666
Total liabilities and equity	11,752	13,433	18,151	22,730	22,533	25,643
Common shares outstanding (cover page) millions of shares	260	255	257	258	257	254

Fiscal years (VRTX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	2,712	2,342	3,322	3,620	(536)	3,953
Stock-based compensation	429	441	491	581	699	686
Depreciation and amortization	110	126	148	181	207	210
Net cash from operating activities	3,254	2,644	4,130	3,537	(493)	3,631
Purchases of property and equipment	260	235	205	200	298	438
Net cash from investing activities	99	(341)	(321)	(3,142)	(3,770)	(945)
Share repurchases	539	1,425	0	428	1,177	2,017
Net cash from financing activities	(505)	(1,478)	(68)	(562)	(1,495)	(2,261)
Net change in cash	2,868	811	3,712	(140)	(5,800)	516

The peer list for this company is being put together from its industry's latest filings. Reload the page in a minute to see it.

Not investment advice. Not affiliated with the U.S. SEC.